BNP Paribas Financial Markets Acquires 72,255 Shares of Revvity, Inc. (NYSE:RVTY)

BNP Paribas Financial Markets grew its holdings in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 51.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212,367 shares of the company's stock after acquiring an additional 72,255 shares during the period. BNP Paribas Financial Markets owned about 0.17% of Revvity worth $23,702,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assetmark Inc. lifted its stake in shares of Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock valued at $30,000 after buying an additional 259 shares in the last quarter. Optiver Holding B.V. bought a new position in shares of Revvity in the fourth quarter worth about $33,000. Quarry LP boosted its stake in shares of Revvity by 45.7% in the fourth quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after acquiring an additional 95 shares during the period. Millstone Evans Group LLC bought a new stake in Revvity during the 4th quarter valued at approximately $38,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock worth $43,000 after purchasing an additional 138 shares in the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Stock Performance

Shares of NYSE:RVTY opened at $91.22 on Friday. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a 12 month low of $88.53 and a 12 month high of $129.50. The company has a market capitalization of $10.96 billion, a price-to-earnings ratio of 41.28, a PEG ratio of 3.82 and a beta of 1.02. The firm's 50-day moving average is $100.83 and its 200 day moving average is $111.17.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.05. The firm had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The company's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.98 earnings per share. Research analysts predict that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Friday, July 18th. Revvity's dividend payout ratio is presently 11.91%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. The Goldman Sachs Group decreased their price target on shares of Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. UBS Group upgraded Revvity from a "neutral" rating to a "buy" rating and cut their price objective for the company from $145.00 to $115.00 in a research report on Thursday, May 1st. Wells Fargo & Company decreased their target price on Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, Sanford C. Bernstein cut Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.